Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: J Neuroimmunol. 2013 Jun 12;262(0):11–18. doi: 10.1016/j.jneuroim.2013.05.012

Table 1.

Disease severity and incidence were significantly increased in trkB +/− mice compared to their wt littermates (trkB+/+) with less potent disease induction, however, trkB +/− mice fared similar to wt littermates with more potent disease inductiona

Immunization
conditions		 Mice Incidence of
EAE (%)		 Mean Day of
Onsetb 		Mean
cumulative
Clinical
Scorec 		Mean
Maximum
Severityd 		Mortality
Less potent trkB +/+ 2/5 (40%) 11.0 ± 0.0 32.8 ± 6.7 1.0 ± 1.4 0/5 (0%)
trkB +/− 5/5 (100%)* 13.2 ± 2.7 56.6 ± 36.6 3.6 ± 1.5* 1/5 (20%)
More potent trkB +/+ 5/5 (100%) 14.4 ± 0.5 79.1 ± 29.5 3.1 ± 1.3 0/5 (0%)
trkB +/− 4/4 (100%) 14.8 ± 2.5 54.5 ± 12.3 2.5 ± 0.0 0/4 (0%)
a

trkB+/− and age- and gender-matched female wide type littermates (trkB+/+) (n=4-5 each group) were immunized with MOG35-55(200μg)/CFA containing M. Tbc (1mg/ml ‘less potent’ or 5mg/ml ‘more potent’)/PT(400ng ‘less potent’ or 600ng ‘more potent’) using two immunization protocols resulting in mild or severe disease induction in wild type littermates trkB+/+ mice. Mice (n=4-5 each group) were scored daily, and the mean score of each group ± SD is shown.

b

Mean of the first sign of clinical scores for each animal.

c

Mean of the sum of scores for each animal over the entire observation period (48 days).

d

Mean of the highest clinical score exhibited by individual animals within a group during the entire course of EAE.

*

p< 0.05 by t test between trkB+/− and +/+ (wt) under the same immunization conditions.